- The Accelerate Arc System cuts hours of wait time and numerous manual steps to deliver Identification (ID) results
- Unlocks rapid microbial ID from positive blood cultures for the large installed base of MALDI system users
TUCSON, Ariz., March 28, 2022 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX) an in-vitro diagnostics company dedicated to providing solutions for the global challenges of antibiotic resistance and sepsis, today announced the launch of the Accelerate Arc system, comprised of the Arc Module and BC Kit, an automated path to rapid and accurate microbial identification for positive blood cultures.
Designed for labs with MALDI, the Accelerate Arc Module is a novel application of inline centrifugal and sample preparation techniques, providing a suspension of cleaned and concentrated microbial cells, which together with the blood culture (BC) kit, allow for direct transfer to a MALDI spotting plate.
The simple load-and-go workflow eliminates the need for batching multiple specimen tests, cutting hours off the wait for microbial ID results for positive blood cultures. The Arc module requires just 2-3 minutes of hands-on time to run and is simple enough to be used on all shifts, by any laboratory technician.
In addition, the Accelerate Arc system is designed to eliminate the need for overnight culture incubation for current MALDI users, while reducing the likelihood of cross reactivity and potential false positive results that come with rapid multi-targeted molecular tests. For some labs, roughly 30% of molecular tests turn up as contaminants, increasing the number of expensive rapid multi-targeted molecular kits that are wasted.
"I am excited to be launching this new system as promised and with strong early performance data. The total cost to rapidly identify organisms from positive blood cultures could be at least fifty percent less than what you're paying today for a rapid molecular ID solution," said Jack Phillips, President, and CEO of Accelerate Diagnostics. "When you think of the extreme pressure that labs are under today, the Arc is a fast and inexpensive diagnostic tool which frees up valuable technician time by automating the MALDI workflow.
Recent studies conducted on the efficacy and time-saving benefits of the Arc study will be presented at the upcoming 32nd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2022). The Arc is currently intended for Research Use Only and is not for use in diagnostic procedures.
About Accelerate Diagnostics, Inc.
Accelerate Diagnostics, Inc. is an in vitro diagnostics company dedicated to providing solutions for the global challenges of antibiotic resistance and sepsis. The Accelerate Pheno® system and Accelerate PhenoTest® BC kit combine several technologies aimed at reducing the time clinicians must wait to determine the most optimal antibiotic therapy for deadly infections. The FDA cleared system and kit fully automate the sample preparation steps to report phenotypic antibiotic susceptibility results in approximately 7 hours direct from positive blood cultures. Recent external studies indicate the solution offers results 1–2 days faster than existing methods, enabling clinicians to optimize antibiotic selection and dosage specific to the individual patient days earlier.
"Accelerate Diagnostics" and diamond shaped logos and marks are registered trademarks of Accelerate Diagnostics, Inc. Any trade, product or service name referenced in this document using the name "Accelerate" is a trademark and/or property of Accelerate Diagnostics, Inc. All other company and product names may be trademarks, registered trademarks, or service marks of the companies with which they are associated.
For more information about the company, its products and technology, or recent publications, visit axdx.com.
Certain of the statements made in this press release are forward looking. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Such forward looking statements include any implication that the results of the new landmark study will be realized at other customers using the Accelerate Pheno system. Information about the risks and uncertainties faced by Accelerate Diagnostics is contained in the section captioned "Risk Factors" in the company's most recent Annual Report on Form 10-K, filed with the Securities and Exchange Commission on March 2, 2021, and in any other reports that the company files with the Securities and Exchange Commission. The company's forward-looking statements could be affected by general industry and market conditions, and regulatory approvals. Except as required by federal securities laws, the company undertakes no obligation to update or revise these forward-looking statements to reflect new events, uncertainties, or other contingencies.
Investor Relations Contact
Media Relations Contact
SOURCE Accelerate Diagnostics, Inc.